Wrinkle relaxers,
decoded.
A research-grade look at how expression lines form, how botulinum toxin works, where it is injected, and what FDA labels and clinical evidence say about results, longevity, and safety.
Evidence-basedBrickell, Miami19 cited sourcesReviewed 2026
What a wrinkle relaxer can and cannot do
Botulinum toxin type A works on dynamic wrinkles: the lines made by repeated muscle movement, like frown lines, forehead lines, and crow's feet. By briefly quieting the targeted muscle, it smooths those lines and can help keep them from deepening into static lines over time.4,9
It is not a filler and not a face-lift. It does not restore lost volume, and on its own it does not erase deep static creases. Brand matters less than anatomy, dose, and the injector's hand.1,5 See how our Brickell team approaches wrinkle relaxers in practice.
Dynamic lines, and how they become static
Every time you frown, squint, or raise your brows, a facial muscle folds the skin above it. Early on the line vanishes when your face relaxes. Over time, and as collagen and elastin decline, that fold can become visible even at rest.4,9
How a few units relax a muscle
Botulinum toxin blocks acetylcholine release at the nerve-muscle junction. Without that chemical signal, the targeted muscle relaxes, the skin above it stops folding as hard, and the line softens.5,6
Where it goes, and why
Each treatment area targets a specific muscle. Tap a region on the face to see the muscle, typical Botox-unit dose, and FDA status. Doses vary by anatomy and product.1,16
Six toxins, one job — so which?
All six FDA-approved products are botulinum toxin type A. They differ in onset, duration, unit scale, formulation, and spread profile.1,5,13 For a side-by-side breakdown of the three we use most, read a deeper comparison of Botox, Dysport, and Xeomin.
| Product | FDA cosmetic use | Onset | Duration | Units | What sets it apart |
|---|---|---|---|---|---|
| Botox onabotulinumtoxinA | Glabella 2002; crow's feet 2013; forehead 2017; platysma 2024 | 3-5 days | 3-4 months | Reference standard | Complexing proteins + human albumin |
| Dysport abobotulinumtoxinA | Glabellar lines, 2009 | 2-3 days | 3-4 months | ~2.5-3 units per Botox unit | Wider spread profile |
| Xeomin incobotulinumtoxinA | Glabellar lines, 2011 | 3-6 days | 3-4 months | ~1:1 with Botox | No complexing proteins |
| Jeuveau prabotulinumtoxinA | Glabellar lines, 2019 | 2-5 days | 3-4 months | ~1:1 with Botox | Aesthetic-only toxin |
| Daxxify daxibotulinumtoxinA | Glabellar lines, 2022 | 1-2 days | ~6 months | Different scale | Peptide-stabilized; no human albumin |
| Letybo letibotulinumtoxinA | Glabellar lines, 2024 | 2-3 days | 3-4 months | ~1:1 with Botox | Type A toxin |
Wondering which areas you actually need?
Our Brickell injectors map your movement, discuss your goals, and build a conservative plan with the right product and dose for your face.
Side effects, risks, and who should wait
In trained hands, cosmetic botulinum toxin has an excellent safety record. Most side effects are minor, temporary, and injection-related.5,8
| Effect | How common | What to know |
|---|---|---|
| Bruising or swelling | Common, minor | Usually resolves in days. |
| Headache | Usually mild | Short-lived after treatment. |
| Eyelid droop | Uncommon | Temporary and strongly technique-dependent.8 |
| Brow heaviness | Uncommon | Avoided with balanced forehead and frown-area dosing. |
| Spread of toxin effect | Boxed warning | Relevant to high therapeutic doses; the Botox label notes no confirmed serious distant-spread cases at labeled cosmetic doses.1 |
Frequently asked questions
Most people describe a quick pinch with each tiny injection. There is essentially no downtime, though you should avoid heavy exercise, lying flat, and rubbing the area for a few hours.
Softening starts in 1-3 days, and the full effect lands around two weeks. That is when touch-ups are assessed.
Not with conservative, anatomy-led dosing. A frozen look comes from too much product in the wrong places.
The sensible time is when a line starts to linger after your face relaxes, not before any line exists.
Sources and further reading
Primary FDA prescribing information, regulatory records, professional-society statistics, and peer-reviewed literature.
- BOTOX Cosmetic (onabotulinumtoxinA) Prescribing Information. AbbVie/Allergan; October 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103000s5316s5319s5323s5326s5331lbl.pdf
- Botox Cosmetic FDA Approval History: glabellar lines, lateral canthal lines, forehead lines, and platysma bands. https://www.drugs.com/history/botox-cosmetic.html
- BOTOX Cosmetic Celebrates 20 Years Since First U.S. FDA Approval. AbbVie/Allergan Aesthetics; 2022. https://news.abbvie.com/2022-04-13-BOTOX-R-Cosmetic-onabotulinumtoxinA-Celebrates-20-Years-Since-First-U-S-FDA-Approval
- Botulinum Toxin Procedures: A Practical Approach to Cosmetic Injections. American Family Physician. 2026. https://www.aafp.org/afp/2026/0500/botulinum-toxin-procedures
- Padda IS, Tadi P. Botulinum Toxin. StatPearls. NCBI Bookshelf; 2023. https://www.ncbi.nlm.nih.gov/books/NBK557387/
- Botulinum Toxin: Mechanism of Action and Clinical Use. OpenAnesthesia; 2023. https://www.openanesthesia.org/keywords/botulinum-toxin-mechanism-of-action-and-clinical-use/
- Modulating Neuromuscular Junction Density Changes in Botulinum Toxin-Treated Orbicularis Oculi Muscle. IOVS. 2011. https://iovs.arvojournals.org/article.aspx?articleid=2128266
- Nestor MS, et al. Botulinum toxin-induced blepharoptosis: anatomy, etiology, prevention, and therapeutic options. J Cosmet Dermatol. 2021. https://onlinelibrary.wiley.com/doi/10.1111/jocd.14361
- Binder WJ. Long-term effects of botulinum toxin type A on facial lines: a comparison in identical twins. Arch Facial Plast Surg. 2006.
- ISAPS International Survey on Aesthetic/Cosmetic Procedures, 2024. https://www.isaps.org/discover/about-isaps/global-statistics/global-survey-2024-full-report-and-press-releases/
- 2024 ASPS Procedural Statistics Report. American Society of Plastic Surgeons. https://www.plasticsurgery.org/plastic-surgery-statistics
- Carr WW, Jain N, Sublett JW. Immunogenicity of Botulinum Toxin Formulations. Toxins. 2021.
- Rappl T, et al. Onset and duration of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in glabellar lines. 2013.
- Carruthers J, et al. DaxibotulinumtoxinA for Injection: SAKURA program. Dermatol Surg. 2022.
- Botox and the Ocular Surface. American Academy of Ophthalmology, EyeNet; 2023. https://www.aao.org/eyenet/article/botox-aids-the-ocular-surface
- Cosmetic Use of Botulinum Toxin. Review of Ophthalmology; 2012. https://www.reviewofophthalmology.com/article/cosmetic-use-of-botulinum-toxin
- Optimizing Botulinum Toxin Injections in the Platysma Muscle Based on Motor Nerve Distribution. J Cosmet Dermatol. 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202260/
- Novel Injection Technique of Botulinum Toxin to Reduce Facial Rhytids: A Cadaver Study. 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069872/
- AAFPRS Annual Survey, 2023: rise in patients under 30 seeking preventative treatment.